ISG15
Ubiquitin-like protein ISG15
Protein Summary
Ubiquitin-like protein which plays a key role in the innate immune response to viral infection either via its conjugation to a target protein (ISGylation) or via its action as a free or unconjugated protein. ISGylation involves a cascade of enzymatic reactions involving E1, E2, and E3 enzymes which catalyze the conjugation of ISG15 to a lysine residue in the target protein. Its target proteins include IFIT1, MX1/MxA, PPM1B, UBE2L6, UBA7, CHMP5, CHMP2A, CHMP4B and CHMP6. Can also isgylate: EIF2AK2/PKR which results in its activation, DDX58/RIG-I which inhibits its function in antiviral signaling response, EIF4E2 which enhances its cap structure-binding activity and translation-inhibition activity, UBE2N and UBE2E1 which negatively regulates their activity, IRF3 which inhibits its ubiquitination and degradation and FLNB which prevents its ability to interact with the upstream activators of the JNK cascade therby inhibiting IFNA-induced JNK signaling. Exhibits antiviral activity towards b ...more
- ENST00000379389
- ENSP00000368699
- ENSG00000187608
- ENST00000649529
- ENSP00000496832
- G1P2
- UCRP
- G1P2
- IP17
- UCRP
- IFI15
- IMD38
- hUCRP
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
virus perturbation | 1 | ||
PubMedID | 0.96 | ||
small molecule perturbation | 0.88 | ||
transcription factor perturbation | 0.8 | ||
biological term | 0.78 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 667.25 (req: < 5)
Gene RIFs: 182 (req: <= 3)
Antibodies: 525 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 667.25 (req: >= 5)
Gene RIFs: 182 (req: > 3)
Antibodies: 525 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 15
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0